PharmaSource Editorial Content

  1. CDMO Quality Oversight: How FDA And Pharma Leaders Are Rethinking Data, AI, And Culture 9/2/2026

    Discover strategies for risk-based governance, AI-enabled quality management, stronger collaboration, and fostering a culture that supports long-term operational excellence.

  2. ADC CDMO Selection For Small Biotech 8/31/2026

    Manufacturing is a critical factor in ADC success. Discover how to align CDMO capabilities with molecule complexity, mitigate risks, and navigate capacity limits.

  3. CDMO Selection For Small Biotech: Amit Jain On Avoiding Costly Transfers 8/20/2026

    Make smarter outsourcing decisions early. Reduce the risk of costly tech transfers, evaluate capacity needs, speed development timelines, and strengthen manufacturing partnerships.

  4. Beyond The VC Round: Creative Financing Strategies For Biotech's Bear Market 8/3/2026

    Pretzel Therapeutics COO Baruch Harris shares creative financing strategies, from spinouts to non-dilutive funding, that keep biotech companies alive when VC capital dries up. Access the full conversation to build your capital roadmap.

  5. What Will It Actually Take To Build A Resilient Global Vaccine Supply Chain? 8/3/2026

    U.S. funding cuts could leave 75 million children without routine vaccines. Five supply chain leaders explain what resilience actually requires and what's at stake if the sector fails to act.

  6. How Sanofi Navigates Regulatory CMC Across Global Markets 8/3/2026

    Sanofi's Manda Pasarkar shares 20+ years of regulatory CMC expertise, covering FDA, EMA, and PMDA differences, CDMO partnerships, ICH guidelines, and AI's emerging role in global drug approvals.

  7. Tariffs, FDA Chaos, And BioSecure: How CDMOs Should Operate 8/3/2026

    Tariffs, FDA workforce cuts, and a stalled BioSecure Act are reshaping CDMO strategy. Get the full policy breakdown to stress-test your supply chain planning now.

  8. Reshoring Pressure Meets Manufacturing Reality 7/27/2026

    U.S. pharma can't reshore what domestic capacity can't absorb. Senior leaders from Takeda, Biogen, Eli Lilly, and others reveal why tariff pressure is colliding with a sterile fill-finish shortage, workforce gaps, and ADC capacity bottlenecks.

  9. CDMO Live Europe 2026: Partnerships For An Uncertain World 7/27/2026

    112 pages of executive insight from CDMO Live Europe 2026: tariffs, geopolitics, supply resilience, AI in manufacturing, and why strategic partnerships remain aspirational for most.

  10. Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report 7/27/2026

    Senior pharma leaders from Pfizer, Bayer, BioNTech and others debunk dual sourcing myths and reveal what separates strategic CDMO partnerships from transactional ones.